nach oben

Archives of Gynecology and Obstetrics

Erschienen in:

09.11.2020 | Maternal-Fetal Medicine

Should pregnant women with anticoagulant prophylaxis benefit from scheduled delivery?

verfasst von: Florence Feucht, Pierre Richart, Nathalie Trillot, Louise Ghesquiere, Charles Garabedian, Damien Subtil

Erschienen in: Archives of Gynecology and Obstetrics | Ausgabe 5/2021

Einloggen, um Zugang zu erhalten

Abstract

Purpose

When vaginal delivery is considered in women with low-molecular-weight heparin (LMWH) treatment, epidural analgesia is contraindicated for 12–24 h after the last injection. We evaluated the proportion of epidural analgesia depending on whether this is scheduled delivery (labor induction after stopping LMWH) or unscheduled delivery (stopping LMWH at labor onset).

Methods

Retrospective hospital study running from 2015 to 2017. Inclusion criteria for patients with LMWH treatment were: singleton pregnancy, gestational age ≥ 38 weeks of gestation and possible vaginal delivery. The primary endpoint was the epidural analgesia rate. Secondary endpoints included risks for caesarean section, deep vein thrombosis, and postpartum hemorrhage.

Results

Among 129 patients, 54 had scheduled delivery (41.9%). In practice, only 44 of them had labor induction (81.5%) and 54 of the 75 patients in the unscheduled delivery group had spontaneous delivery (72.0%). There was no significant difference in the rate of epidural analgesia between the "scheduled" and "unscheduled" groups (52/54 (96.3%) vs. 66/75 (88.0%) (p = 0.12)), and no difference in the secondary endpoints.

Conclusion

High access rates to epidural analgesia are observed in both scheduled and unscheduled deliveries. Scheduled delivery does not appear to be a really advantageous strategy for women with LMWH prophylaxis.

Bates SM, Greer IA, Middeldorp S, Veenstra DL, Prabulos A-M, Vandvik PO et al (2012) VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141(2 Suppl):e691S–e736S. https://doi.org/10.1378/chest.11-2300CrossRefPubMedPubMedCentral

Bowyer L (2008) The Confidential Enquiry into Maternal and Child Health (CEMACH). Saving Mothers’ Lives: reviewing maternal deaths to make motherhood safer 2003–2005. The Seventh Report of the Confidential Enquiries into Maternal Deaths in the UK. Obstet Med 1(1):54–54. https://doi.org/10.1258/om.2008.080017CrossRefPubMedCentral

Schutte J, Steegers E, Schuitemaker N, Santema J, de Boer K, Pel M et al (2010) Rise in maternal mortality in the Netherlands. BJOG Int J Obstet Gynaecol. 117:399–406CrossRef

Saucedo M, Deneux-Tharaux C, Bouvier-Colle M-H (2013) Maternal mortality in France, 2007–2009. J Gynecol Obstet Biol Reprod. 42:613–627CrossRef

Greer IA (2006) Anticoagulants in pregnancy. J Thromb Thrombolysis. 21:57–65CrossRef

Deruelle P, Coulon C (2007) The use of low-molecular-weight heparins in pregnancy–how safe are they? Curr Opin Obstet Gynecol. 19:573–577CrossRef

Horlocker TT, Wedel DJ, Benzon H, Brown DL, Enneking FK, Heit JA et al (2003) Regional anesthesia in the anticoagulated patient: defining the risks (the second ASRA Consensus Conference on Neuraxial Anesthesia and Anticoagulation). Reg Anesth Pain Med. 28:172–197PubMed

Gogarten W, Vandermeulen E, Van Aken H, Kozek S, Llau JV, Samama CM et al (2010) Regional anaesthesia and antithrombotic agents: recommendations of the European Society of Anaesthesiology. Eur J Anaesthesiol. 27:999–1015CrossRef

Collins J, Bowles L, MacCallum PK (2005) Prevention and management of venous thromboembolism in pregnancy. Br J Hosp Med Lond Engl 2016(120):S26-34

10.

Lindqvist PG, Bremme K, Hellgren M, for the Swedish Society of Obstetrics and Gynecology (SFOG) Working Group on Hemostatic Disorders (Hem-ARG) (2011) Efficacy of obstetric thromboprophylaxis and long-term risk of recurrence of venous thromboembolism. Acta Obstet Gynecol Scand. 90:648–653CrossRef

11.

Philippe A, Ruivard M, Auclair C, Accoceberry M, Bonnin M, Pouly J-L et al (2015) Anticoagulation and peripartum management. Gynecol Obstet Fertil. 71:322–329

12.

Roueli A, Cesario E, Amsellem J, Agman A, Vauthier-Brouzes D, Nizard J (2017) Is a therapeutic anticoagulation window needed for delivery when using prophylactic low molecular weight heparin during pregnancy? A retrospective monocentric study. Eur J Obstet Gynecol Reprod Biol. 215:118–123CrossRef

13.

Boulvain M, Marcoux S, Bureau M, Fortier M, Fraser W (2001) Risks of induction of labour in uncomplicated term pregnancies. Paediatr Perinat Epidemiol. 15:131–138CrossRef

14.

Cammu H, Martens G, Ruyssinck G, Amy J-J (2002) Outcome after elective labor induction in nulliparous women: a matched cohort study. Am J Obstet Gynecol. 186:240–244CrossRef

15.

Grobman WA et al (2018) Labor induction versus expectant management in low-risk nulliparous women. N Engl J Med. 379(6):513–523CrossRef

16.

Le Ray C, Carayol M, Bréart G, Goffinet F, PREMODA Study Group (2007) Elective induction of labor: failure to follow guidelines and risk of cesarean delivery. Acta Obstet Gynecol Scand. 86:657–665CrossRef

17.

Lepercq J, Conard J, Borel-Derlon A, Darmon JY, Boudignat O, Francoual C et al (2001) Venous thromboembolism during pregnancy: a retrospective study of enoxaparin safety in 624 pregnancies. BJOG Int J Obstet Gynaecol. 108:1134–1140CrossRef

18.

Sanson BJ, Lensing AW, Prins MH, Ginsberg JS, Barkagan ZS, Lavenne-Pardonge E et al (1999) Safety of low-molecular-weight heparin in pregnancy: a systematic review. Thromb Haemost. 81:668–672CrossRef

19.

Weitz JI (1997) Low-Molecular-Weight Heparins. N Engl J Med. 337:688–699CrossRef

20.

Bara L, Samama M (1988) Pharmacokinetics of low molecular weight heparins. Acta Chir Scand Suppl. 543:65PubMed

21.

Pabinger I, Grafenhofer H, Kaider A, Kyrle PA, Quehenberger P, Mannhalter C et al (2005) Risk of pregnancy-associated recurrent venous thromboembolism in women with a history of venous thrombosis. J Thromb Haemost JTH. 3:949–954CrossRef

22.

De Stefano V, Martinelli I, Rossi E, Battaglioli T, Za T, Mannuccio Mannucci P et al (2006) The risk of recurrent venous thromboembolism in pregnancy and puerperium without antithrombotic prophylaxis. Br J Haematol. 135:386–391CrossRef

23.

Henderson J, Redshaw M (2013) Women’s experience of induction of labor: a mixed methods study. Acta Obstet Gynecol Scand. 92:1159–1167PubMed

24.

Bates SM et al (2018) American Society of Hematology 2018 guidelines for management of venous thromboembolism: venous thromboembolism in the context of pregnancy. Blood Adv. 2:3317–3359CrossRef

Titel: Should pregnant women with anticoagulant prophylaxis benefit from scheduled delivery?
verfasst von: Florence Feucht
Pierre Richart
Nathalie Trillot
Louise Ghesquiere
Charles Garabedian
Damien Subtil
Publikationsdatum: 09.11.2020
Verlag: Springer Berlin Heidelberg
Erschienen in: Archives of Gynecology and Obstetrics / Ausgabe 5/2021
Print ISSN: 0932-0067
Elektronische ISSN: 1432-0711
DOI: https://doi.org/10.1007/s00404-020-05850-6

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen

Springer Medizin

Should pregnant women with anticoagulant prophylaxis benefit from scheduled delivery?